Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/1999
11/18/1999WO1999058641A2 Nt2lp, novel g-protein coupled receptors having homology to neurotensin-2 receptors
11/18/1999WO1999058640A2 Mct-1, a human oncogene
11/18/1999WO1999058573A1 Diagnosis and treatment of hepatic disorders
11/18/1999WO1999058572A1 Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
11/18/1999WO1999058571A2 Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
11/18/1999WO1999058570A2 Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis
11/18/1999WO1999058569A1 PLASMIN INHIBITORS FROM THE AUSTRALIAN BROWN SNAKE $i(PSEUDONAJA TEXTILIS TEXTILIS)
11/18/1999WO1999058568A1 Gprw receptor
11/18/1999WO1999058567A1 GABAB1b RECEPTOR
11/18/1999WO1999058566A1 INHIBITION OF p53 FUNCTION BY A p53-DERIVED SUBSTANCE
11/18/1999WO1999058565A1 Cystatin-related protein
11/18/1999WO1999058564A1 Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use
11/18/1999WO1999058563A2 Moraxella catharralis proteins
11/18/1999WO1999058560A2 Prostapin gene and protein and uses thereof
11/18/1999WO1999058559A2 Factors affecting tumor necrosis factor receptor releasing enzyme activity
11/18/1999WO1999058558A2 Cell signaling proteins
11/18/1999WO1999058557A2 Dimers of the hla-b27 heavy chain extracellular domain and uses thereof
11/18/1999WO1999058552A2 Peptides that ellicit t, cellular immunity
11/18/1999WO1999058548A1 Mmsc2 - an mmaci interacting protein
11/18/1999WO1999058547A1 A genetically modified manganese superoxide dismutase for treating oxidative damage
11/18/1999WO1999058546A1 Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene
11/18/1999WO1999058515A1 Novel spiro compounds or salts thereof and preventives/remedies for autoimmune diseases and ap-1 inhibitors containing the same
11/18/1999WO1999058155A1 Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
11/18/1999WO1999058154A1 Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
11/18/1999WO1999058153A1 Methods of diagnosing and modulating autoimmunity
11/18/1999WO1999058150A1 Preventives/remedies for hepatic cirrhosis
11/18/1999WO1999058147A1 APOPTOSIS OF NAIVE HUMAN NK CELLS BY CROSSLINKING OF THEIR FcγRIIIa MOLECULES WIHT A RAT IgG2b (LO-CD2a/BTI-322) OR ITS IgG1 HUMANIZED MONOCLONAL ANTIBODY
11/18/1999WO1999058145A2 Immunomodulators for vaccines
11/18/1999WO1999058144A1 Methods of enhancing functioning of the large intestine
11/18/1999WO1999058143A1 Utilization of interferon alpha 5 in the treatment of viral hepatopathies
11/18/1999WO1999058142A1 Use of anti-prolactin agents to treat proliferative conditions
11/18/1999WO1999058141A1 Indolicidin analogs and methods of using same
11/18/1999WO1999058140A1 Methods to increase white blood cell survival after chemotherapy
11/18/1999WO1999058139A2 Methods for detecting and inhibiting angiogenesis
11/18/1999WO1999058137A1 Bio-pharmaceutical preparation containing a live culture of bacillus and method for treating viral and bacterial infections as well as immuno-deficiency conditions
11/18/1999WO1999058135A1 Compositions for the treatment of tumors, and uses thereof
11/18/1999WO1999058133A2 Anti-diarrheal and method for using the same
11/18/1999WO1999058126A1 Use of neomycin for treating angiogenesis-related diseases
11/18/1999WO1999058110A1 Mucoadhesive compositions for administration of biologically active agents to animal tissue
11/18/1999WO1999058098A2 HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
11/18/1999WO1999058097A2 Use of anti-prolactin agents to treat proliferative conditions
11/18/1999WO1999058000A1 Nutritional composition for the treatment of pressure ulcers
11/18/1999WO1999057956A2 Transcription factor regulating fgf-2 and variants thereof
11/18/1999WO1999052562A3 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
11/18/1999WO1999051740A3 Nucleotide sequence expressing human fatty acid transport protein and corresponding aminoacid, use for the regulation of fatty acids metabolism
11/18/1999WO1999051253A3 Immune response modulation
11/18/1999WO1999050295A3 Agouti-related protein analogs and methods of use
11/18/1999WO1999050287A3 P40 protein acts as an oncogene
11/18/1999WO1999050286A3 Antioxidant peptides derived from apolipoprotein a-iv
11/18/1999WO1999050285A3 Production methods and uses of a retrovirus
11/18/1999WO1999049909A3 Revascularization apparatus having coaxial channeling and injecting means
11/18/1999WO1999049855A3 Ipg antagonists for the treatment of conditions involving mast cells, basophils and eosinophils
11/18/1999WO1999048915A9 Orphan nuclear receptor
11/18/1999WO1999047673A3 Isolated mammalian membrane protein genes and related reagents
11/18/1999WO1999047652A3 Novel rnase-like protein and its use
11/18/1999WO1999047153A3 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY rho GTPase FUNCTION INHIBITORS
11/18/1999WO1999047150A9 A pharmaceutical composition containing ezrin mutated on tyrosine 353
11/18/1999WO1999046364A9 Vascular endothelial growth factor 2
11/18/1999WO1999046284A9 Molecules that home to various selected organs or tissues
11/18/1999WO1999046283A9 Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
11/18/1999WO1999046281A9 Novel polypeptides and nucleic acids encoding the same
11/18/1999WO1999045962A9 Transgenic non-human animals capable of producing heterologous antibodies
11/18/1999WO1999045949A3 Use of follistatin to modulate gdf-8 and bmp-11
11/18/1999WO1999043834A3 P-selectin ligand protein, including tetrameric fusion proteins
11/18/1999WO1999042584A9 Apoptosis inducing molecule ii and methods of use
11/18/1999WO1999042076A9 Compounds and methods for immunotherapy and diagnosis of tuberculosis
11/18/1999WO1999038981A3 Human protein kinase molecules
11/18/1999WO1999037803A9 INHIBITION OF DNA MODULATION CAUSED BY MUTATED p53
11/18/1999WO1999036550A3 Human protease molecules
11/18/1999WO1999036099A8 Sustained release compositions, process for producing the same and utilization thereof
11/18/1999WO1999036094A3 Composition and method for treating metastatic tumors or cancer induced by cells expressing sv40 tumor antigen
11/18/1999WO1999028475A3 Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
11/18/1999WO1999028349A3 CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
11/18/1999WO1999027098A3 A-33 related antigens and their pharmacological uses
11/18/1999WO1998037909A9 Methods and compositions for optimization of oxygen transport by cell-free systems
11/18/1999DE19821951A1 Orally administered solid or liquid cyclosporin compositions
11/18/1999DE19821483A1 New imidazolidine derivatives useful as leukocyte adhesion and migration inhibitors and/or VLA-4 receptor antagonists for treating E.G. inflammatory and allergic disorders
11/18/1999CA2685270A1 Expression vectors for stimulating an immune response and methods of using the same
11/18/1999CA2404693A1 97 human secreted proteins
11/18/1999CA2332109A1 97 human secreted proteins
11/18/1999CA2331998A1 Novel spiro compounds or salts thereof and preventives/remedies for autoimmune diseases and ap-1 inhibitors containing the same
11/18/1999CA2331832A1 E.coli heat-labile enterotoxin subunit b (etxb) as an immunomodulator
11/18/1999CA2331754A1 Methods of determining protein activity levels using gene expression profiles
11/18/1999CA2331620A1 Use of neomycin for treating angiogenesis-related diseases
11/18/1999CA2331569A1 Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
11/18/1999CA2331455A1 Novel molecule and diagnosis method
11/18/1999CA2331350A1 Mucoadhesive compositions for administration of biologically active agents to animal tissue
11/18/1999CA2331314A1 Anti-diarrheal and method for using the same
11/18/1999CA2331115A1 New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines
11/18/1999CA2331061A1 Complex formed by a peptide and a major histocompatibility complex at the surface of phages
11/18/1999CA2330000A1 Diagnosis and treatment of hepatic disorders
11/18/1999CA2328606A1 Antibodies to cd23, derivatives thereof, and their therapeutic uses
11/18/1999CA2328601A1 Preventives/remedies for hepatic cirrhosis
11/18/1999CA2328521A1 Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
11/18/1999CA2328520A1 Use of anti-prolactin agents to treat proliferative conditions
11/18/1999CA2328518A1 Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
11/18/1999CA2328493A1 Transgenic plant-derived human blood coagulation factors
11/18/1999CA2328492A1 Human deadenylating nuclease, its preparation and use
11/18/1999CA2328429A1 Basb028 polypeptides and polynucleotides encoding therefor from moraxella catarrhalis
11/18/1999CA2328414A1 Methods for detecting and inhibiting angiogenesis
1 ... 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 ... 3163